LSTA · Lisata Therapeutics Inc
United States · RS rating 23 · As of 2026-11-03
| Price | 1.09 USD |
|---|---|
| 1-day change | +7.9% |
| RS rating (overall / 1M / 3M / 12M) | 23 / 29 / 61 / 16 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 26 / 8 / 41 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +36.0% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +78.4% |
| Market cap (USD) | $30.1M |